a Department of Math and Sciences , Andrew College , Cuthbert , GA , United States.
c Department of Biomedical Sciences , School of Medicine, Florida State University , Tallahassee , FL , United States.
Cancer Biol Ther. 2018 Mar 4;19(3):181-187. doi: 10.1080/15384047.2017.1415677. Epub 2018 Jan 15.
Multidrug resistance (MDR) represents a major hindrance to the efficacy of cancer chemotherapeutics. While surgical resection, radiation, and chemotherapy can be used to reduce tumor size, the subsequent appearance of drug resistant cells is a frequent problem. One of the main contributors to the development of MDR is increased expression of multi-drug resistant protein 1 (MDR1), also known as P-glycoprotein (P-gp). P-gp is a membrane-associated efflux pump that can efficiently remove internalized taxane-base chemotherapeutics thus preventing drug accumulation and maintaining cellular viability. Consequently, investigation into the molecular mechanisms responsible for regulation of P-gp expression is necessary to facilitate treatment of MDR tumors. Using molecular and biochemical approaches, we identified that the micro-RNA, miRNA149, contributes to the development of MDR within malignant mesothelioma cells by regulating the expression of MDR1.
多药耐药（MDR）是癌症化疗疗效的主要障碍。虽然手术切除、放疗和化疗可用于缩小肿瘤体积，但随后出现耐药细胞是一个常见问题。导致 MDR 发展的主要因素之一是多药耐药蛋白 1（MDR1），也称为 P-糖蛋白（P-gp）的表达增加。P-gp 是一种膜相关的外排泵，可以有效地去除内化的紫杉烷类化疗药物，从而防止药物积累并维持细胞活力。因此，有必要研究负责调节 P-gp 表达的分子机制，以促进 MDR 肿瘤的治疗。我们通过分子和生化方法确定，microRNA149 通过调节 MDR1 的表达，有助于恶性间皮瘤细胞中 MDR 的发展。
